XML 21 R7.htm IDEA: XBRL DOCUMENT v3.26.1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Preferred stock conversion
Debt conversion
Transition adjustment
Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Preferred stock conversion
Additional Paid-in Capital
Debt conversion
Accumulated Deficit
Accumulated Deficit
Transition adjustment
Treasury Stock
Accumulated Other Comprehensive (Loss)
Beginning balance (in shares) at Dec. 31, 2022         4,038,927              
Beginning balance at Dec. 31, 2022 $ 59,583     $ (11,510) $ 40 $ 107,704     $ (31,337) $ (11,510) $ (1,179) $ (15,645)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (4,179)               (4,179)      
Unrealized holding gain on available-for-sale securities, net of tax 384                     384
Comprehensive loss (3,795)               (4,179)     384
Share-based compensation expense 105         105            
Vesting of restricted stock (in shares)         10,887              
Ending balance (in shares) at Dec. 31, 2023         4,049,814              
Ending balance at Dec. 31, 2023 44,383       $ 40 107,809     (47,026)   (1,179) (15,261)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (39,882)               (39,882)      
Unrealized holding gain on available-for-sale securities, net of tax (420)                     (420)
Comprehensive loss (40,302)               (39,882)     (420)
Share-based compensation expense $ 184         184            
Vesting of restricted stock (in shares)         15,779              
Ending balance (in shares) at Dec. 31, 2024 3,991,852       4,065,593              
Ending balance at Dec. 31, 2024 $ 4,265       $ 41 107,993     (86,908)     (15,681)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (12,710)               (12,710)      
Unrealized holding gain on available-for-sale securities, net of tax 3,562                     3,562
Comprehensive loss (9,148)               (12,710)     3,562
Common stock issuance (in shares)         110,994,062              
Common stock issuance 1,110       $ 1,110              
Capital raise 81,952         81,952            
Preferred stock/ Debt conversion   $ 5,026 $ 4,643       $ 5,026 $ 4,643        
Warrants 1,599         1,599            
Share-based compensation expense $ 5,233         5,233            
Vesting of restricted stock (in shares)         10,758              
Ending balance (in shares) at Dec. 31, 2025 114,996,672       115,070,413              
Ending balance at Dec. 31, 2025 $ 94,680       $ 1,151 $ 206,446     $ (99,619)   $ (1,179) $ (12,119)